{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T22:29:26Z","timestamp":1769207366370,"version":"3.49.0"},"reference-count":57,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T00:00:00Z","timestamp":1619740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"European Clinical Research Institute"},{"name":"AstraZeneca, Biosensors International and The Medicines Company"},{"name":"Science Foundation Research Professorship Award","award":["15\/RP\/2765"],"award-info":[{"award-number":["15\/RP\/2765"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Historically, aspirin has been the primary treatment for the prevention of ischaemic events in patients with coronary artery disease. For patients undergoing percutaneous coronary intervention (PCI) standard treatment has been 12 months of dual antiplatelet therapy (DAPT) with aspirin and clopidogrel, followed by aspirin monotherapy; however, DAPT is undeniably associated with an increased risk of bleeding. For over a decade novel P2Y12 inhibitors, which have increased specificity, potency, and efficacy have been available, prompting studies which have tested whether these newer agents can be used in aspirin-free antiplatelet regimens to augment clinical benefits in patients post-PCI. Among these studies, the GLOBAL LEADERS trial is the largest by cohort size, and so far has provided a wealth of evidence in a variety of clinical settings and patient groups. This article summarizes the state-of-the-art evidence obtained from the GLOBAL LEADERS and other trials of aspirin-free strategies.<\/jats:p>","DOI":"10.1093\/ehjcvp\/pvab035","type":"journal-article","created":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T13:03:40Z","timestamp":1619701420000},"page":"547-556","source":"Crossref","is-referenced-by-count":3,"title":["Aspirin-free antiplatelet regimens after PCI: insights from the GLOBAL LEADERS trial and beyond"],"prefix":"10.1093","volume":"7","author":[{"given":"Rutao","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Cardiology, Xijing Hospital, Changle West Road 127, Xi'an 710032, China"},{"name":"Department of Cardiology, National University of Ireland, Galway (NUIG), University Road, Galway H91 TK33, Ireland"},{"name":"Department of Cardiology, Radboud University Medical Center, Geert Grooteplein Zuid 8, 6525 GA Nijmegen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sijing","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, National University of Ireland, Galway (NUIG), University Road, Galway H91 TK33, Ireland"},{"name":"Department of Cardiology, Beijing Anzhen Hospital, Anzhen road No.2, Beijing 100029, China"},{"name":"Department of Cardiology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amr","family":"Gamal","sequence":"additional","affiliation":[{"name":"Department of Cardiology, National University of Ireland, Galway (NUIG), University Road, Galway H91 TK33, Ireland"},{"name":"Department of Cardiology, North Cumbria University Hospitals NHS Trust, Newtown Road, Cumbria CA2 7HY, UK"},{"name":"Department of Cardiology, Zagazig University, Zagazig, Sharkia, 44519, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Xijing Hospital, Changle West Road 127, Xi'an 710032, China"},{"name":"Department of Cardiology, National University of Ireland, Galway (NUIG), University Road, Galway H91 TK33, Ireland"},{"name":"Department of Cardiology, Radboud University Medical Center, Geert Grooteplein Zuid 8, 6525 GA Nijmegen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironori","family":"Hara","sequence":"additional","affiliation":[{"name":"Department of Cardiology, National University of Ireland, Galway (NUIG), University Road, Galway H91 TK33, Ireland"},{"name":"Department of Cardiology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Kawashima","sequence":"additional","affiliation":[{"name":"Department of Cardiology, National University of Ireland, Galway (NUIG), University Road, Galway H91 TK33, Ireland"},{"name":"Department of Cardiology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Ono","sequence":"additional","affiliation":[{"name":"Department of Cardiology, National University of Ireland, Galway (NUIG), University Road, Galway H91 TK33, Ireland"},{"name":"Department of Cardiology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert-Jan","family":"van Geuns","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Radboud University Medical Center, Geert Grooteplein Zuid 8, 6525 GA Nijmegen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Vranckx","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Critical Care Medicine, Hartcentrum Hasselt, Jessa Ziekenhuis, Stadsomvaart 11, 3500 Hasselt, Belgium"},{"name":"Faculty of Medicine and Life Sciences, University of Hasselt, Martelarenlaan 42, 3500 Hasselt, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2653-6762","authenticated-orcid":false,"given":"Stephan","family":"Windecker","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Bern University Hospital, Freiburgstrasse 4, 3010 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinobu","family":"Onuma","sequence":"additional","affiliation":[{"name":"Department of Cardiology, National University of Ireland, Galway (NUIG), University Road, Galway H91 TK33, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9636-1104","authenticated-orcid":false,"given":"Patrick W","family":"Serruys","sequence":"additional","affiliation":[{"name":"Department of Cardiology, National University of Ireland, Galway (NUIG), University Road, Galway H91 TK33, Ireland"},{"name":"Department of Cardiology, Imperial College London, Exhibition Rd, London SW7 2BX, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scot","family":"Garg","sequence":"additional","affiliation":[{"name":"Department of Cardiology, East Lancashire Hospitals NHS Trust, Haslingden Rd, Blackburn BB2 3HH, Lancashire, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,4,30]]},"reference":[{"key":"2021110402482602700_pvab035-B1","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1056\/NEJM199812033392303","article-title":"A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators","volume":"339","author":"Leon","year":"1998","journal-title":"N Engl J Med"},{"key":"2021110402482602700_pvab035-B2","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.1093\/eurheartj\/ehx512","article-title":"Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study","volume":"38","author":"Escaned","year":"2017","journal-title":"Eur Heart J"},{"key":"2021110402482602700_pvab035-B3","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1016\/j.jacc.2015.04.017","article-title":"Long-term safety of drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis","volume":"65","author":"Palmerini","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2021110402482602700_pvab035-B4","doi-asserted-by":"crossref","first-page":"371","DOI":"10.4244\/EIJ-D-20-00052","article-title":"Validation of the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria in patients undergoing percutaneous coronary intervention and comparison with contemporary bleeding risk scores","volume":"16","author":"Ueki","year":"2020","journal-title":"EuroIntervention"},{"key":"2021110402482602700_pvab035-B5","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1093\/eurheartj\/ehaa671","article-title":"Validation of high bleeding risk criteria and definition as proposed by the academic research consortium for high bleeding risk","volume":"41","author":"Corpataux","year":"2020","journal-title":"Eur Heart J"},{"key":"2021110402482602700_pvab035-B6","first-page":"804","article-title":"Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial","volume":"38","author":"Valgimigli","year":"2017","journal-title":"Eur Heart J"},{"key":"2021110402482602700_pvab035-B7","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41569-018-0049-1","article-title":"Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention","volume":"15","author":"Capodanno","year":"2018","journal-title":"Nat Rev Cardiol"},{"key":"2021110402482602700_pvab035-B8","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","article-title":"Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial","volume":"392","author":"Vranckx","year":"2018","journal-title":"Lancet"},{"key":"2021110402482602700_pvab035-B9","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/j.jacc.2019.08.1038","article-title":"Ticagrelor alone versus dual antiplatelet therapy from 1 month after drug-eluting coronary stenting","volume":"74","author":"Franzone","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2021110402482602700_pvab035-B10","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without aspirin in high-risk patients after PCI","volume":"381","author":"Mehran","year":"2019","journal-title":"N Engl J Med"},{"key":"2021110402482602700_pvab035-B11","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1001\/jama.2019.8146","article-title":"Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial","volume":"321","author":"Hahn","year":"2019","journal-title":"JAMA"},{"key":"2021110402482602700_pvab035-B12","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2019.8145","article-title":"Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 Randomized Clinical Trial","volume":"321","author":"Watanabe","year":"2019","journal-title":"JAMA"},{"key":"2021110402482602700_pvab035-B13","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1001\/jama.2020.7580","article-title":"Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO Randomized Clinical Trial","volume":"323","author":"Kim","year":"2020","journal-title":"JAMA"},{"key":"2021110402482602700_pvab035-B14","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/j.jcin.2020.06.023","article-title":"Aspirin-free prasugrel monotherapy following coronary artery stenting in patients with stable CAD: the ASET Pilot Study","volume":"13","author":"Kogame","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"key":"2021110402482602700_pvab035-B15","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.4244\/EIJY15M11_07","article-title":"Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial","volume":"12","author":"Vranckx","year":"2016","journal-title":"EuroIntervention"},{"key":"2021110402482602700_pvab035-B16","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ijcard.2020.09.039","article-title":"Regional variation in patients and outcomes in the GLOBAL LEADERS trial","volume":"324","author":"Gao","year":"2021","journal-title":"Int J Cardiol"},{"key":"2021110402482602700_pvab035-B17","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1001\/jamacardio.2019.4296","article-title":"Association of sex with outcomes in patients undergoing percutaneous coronary intervention: a subgroup analysis of the GLOBAL LEADERS randomized clinical trial","volume":"5","author":"Chichareon","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2021110402482602700_pvab035-B18","doi-asserted-by":"crossref","first-page":"e1605","DOI":"10.4244\/EIJ-D-19-00699","article-title":"Ticagrelor monotherapy beyond one month after PCI in ACS or stable CAD in elderly patients: a pre-specified analysis of the GLOBAL LEADERS trial","volume":"15","author":"Tomaniak","year":"2020","journal-title":"EuroIntervention"},{"key":"2021110402482602700_pvab035-B19","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s00392-020-01604-1","article-title":"The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a prespecified sub-analysis of the GLOBAL LEADERS Trial","volume":"109","author":"Ono","year":"2020","journal-title":"Clin Res Cardiol"},{"key":"2021110402482602700_pvab035-B20","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.atherosclerosis.2020.01.002","article-title":"Association of diabetes with outcomes in patients undergoing contemporary percutaneous coronary intervention: pre-specified subgroup analysis from the randomized GLOBAL LEADERS study","volume":"295","author":"Chichareon","year":"2020","journal-title":"Atherosclerosis"},{"key":"2021110402482602700_pvab035-B21","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1007\/s00392-019-01586-9","article-title":"Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial","volume":"109","author":"Tomaniak","year":"2020","journal-title":"Clin Res Cardiol"},{"key":"2021110402482602700_pvab035-B22","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/ccd.28428","article-title":"Clinical relevance of ticagrelor monotherapy following 1-month dual antiplatelet therapy after bifurcation percutaneous coronary intervention: insight from GLOBAL LEADERS trial","volume":"96","author":"Kogame","year":"2020","journal-title":"Catheter Cardiovasc Interv"},{"key":"2021110402482602700_pvab035-B23","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.cjca.2020.01.029","article-title":"Influence of bleeding risk on outcomes of radial and femoral access for percutaneous coronary intervention: an analysis from the GLOBAL LEADERS trial","volume":"37","author":"Gao","year":"2021","journal-title":"Can J Cardiol"},{"key":"2021110402482602700_pvab035-B24","doi-asserted-by":"crossref","first-page":"e006581","DOI":"10.1161\/CIRCOUTCOMES.120.006581","article-title":"Comparison of investigator-reported and clinical event committee-adjudicated outcome events in GLASSY","volume":"14","author":"Leonardi","year":"2021","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2021110402482602700_pvab035-B25","doi-asserted-by":"crossref","first-page":"e1090","DOI":"10.4244\/EIJ-D-19-00202","article-title":"Patient-oriented composite endpoints and net adverse clinical events with ticagrelor monotherapy following percutaneous coronary intervention: insights from the randomised GLOBAL LEADERS trial","volume":"15","author":"Serruys","year":"2019","journal-title":"EuroIntervention"},{"key":"2021110402482602700_pvab035-B26","doi-asserted-by":"crossref","first-page":"e006660","DOI":"10.1161\/CIRCOUTCOMES.120.006660","article-title":"Comparative methodological assessment of the randomized GLOBAL LEADERS trial using total ischemic and bleeding events","volume":"13","author":"Hara","year":"2020","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2021110402482602700_pvab035-B27","doi-asserted-by":"crossref","first-page":"627","DOI":"10.4244\/EIJ-D-20-00145","article-title":"Ticagrelor alone or conventional dual antiplatelet therapy in patients with stable or acute coronary syndromes","volume":"16","author":"Franzone","year":"2020","journal-title":"EuroIntervention"},{"key":"2021110402482602700_pvab035-B28","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1001\/jamacardio.2019.3355","article-title":"Benefit and risks of aspirin in addition to ticagrelor in acute coronary syndromes: a post hoc analysis of the randomized GLOBAL LEADERS trial","volume":"4","author":"Tomaniak","year":"2019","journal-title":"JAMA Cardiol"},{"key":"2021110402482602700_pvab035-B29","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1093\/eurheartj\/ehz453","article-title":"Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial","volume":"40","author":"Serruys","year":"2019","journal-title":"Eur Heart J"},{"key":"2021110402482602700_pvab035-B30","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/j.jacc.2019.08.997","article-title":"Efficacy and safety of ticagrelor monotherapy in patients undergoing multivessel PCI","volume":"74","author":"Takahashi","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2021110402482602700_pvab035-B31","article-title":"Impact of ticagrelor monotherapy on two-year clinical outcomes in patients with long stenting: a post hoc analysis of the global leaders trial","author":"Takahashi","year":"2019","journal-title":"EuroIntervention"},{"key":"2021110402482602700_pvab035-B32","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijcard.2020.07.042","article-title":"Efficacy and safety of one-month DAPT followed by 23-month ticagrelor monotherapy in patients undergoing proximal LAD stenting: insights from the GLOBAL LEADERS trial","volume":"320","author":"Takahashi","year":"2020","journal-title":"Int J Cardiol"},{"key":"2021110402482602700_pvab035-B33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.amjcard.2020.09.057","article-title":"Safety and efficacy of 1-month dual antiplatelet therapy (ticagrelor + aspirin) followed by 23-month ticagrelor monotherapy in patients undergoing staged percutaneous coronary intervention (a sub-study from GLOBAL LEADERS)","volume":"138","author":"Kawashima","year":"2021","journal-title":"Am J Cardiol"},{"key":"2021110402482602700_pvab035-B34","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1002\/ccd.28649","article-title":"Impact of established cardiovascular disease on outcomes in the randomized global leaders trial","volume":"96","author":"Garg","year":"2020","journal-title":"Catheter Cardiovasc Interv"},{"key":"2021110402482602700_pvab035-B35","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12933-020-01153-x","article-title":"Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial","volume":"19","author":"Gao","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"2021110402482602700_pvab035-B36","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1093\/ehjcvp\/pvz052","article-title":"Impact of chronic obstructive pulmonary disease and dyspnoea on clinical outcomes in ticagrelor treated patients undergoing percutaneous coronary intervention in the randomized GLOBAL LEADERS trial","volume":"6","author":"Tomaniak","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2021110402482602700_pvab035-B37","doi-asserted-by":"crossref","DOI":"10.1093\/ehjcvp\/pvaa110","article-title":"Impact of white blood cell count on clinical outcomes in patients treated with aspirin-free ticagrelor monotherapy after percutaneous coronary intervention: insights from the GLOBAL LEADERS Trial","author":"Ono","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2021110402482602700_pvab035-B38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2020.04.010","article-title":"The impact of pre-procedure heart rate on adverse clinical outcomes in patients undergoing percutaneous coronary intervention: results from a 2-year follow-up of the GLOBAL LEADERS trial","volume":"303","author":"Wang","year":"2020","journal-title":"Atherosclerosis"},{"key":"2021110402482602700_pvab035-B39","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.cjca.2019.10.015","article-title":"Association of pulse pressure with clinical outcomes in patients under different antiplatelet strategies after percutaneous coronary intervention: analysis of GLOBAL LEADERS","volume":"36","author":"de Faria","year":"2020","journal-title":"Can J Cardiol"},{"key":"2021110402482602700_pvab035-B40","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/ehjcvp\/pvz051","article-title":"Association between post-percutaneous coronary intervention bivalirudin infusion and net adverse clinical events: a post hoc analysis of the GLOBAL LEADERS study","volume":"6","author":"Chang","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2021110402482602700_pvab035-B41","doi-asserted-by":"crossref","first-page":"e009177","DOI":"10.1161\/CIRCINTERVENTIONS.120.009177","article-title":"Impact of bleeding and myocardial infarction on mortality in all-comer patients undergoing percutaneous coronary intervention","volume":"13","author":"Hara","year":"2020","journal-title":"Circ Cardiovasc Interv"},{"key":"2021110402482602700_pvab035-B42","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/ccd.21314","article-title":"Classification of coronary artery bifurcation lesions and treatments: time for a consensus!","volume":"71","author":"Louvard","year":"2008","journal-title":"Catheter Cardiovasc Interv"},{"key":"2021110402482602700_pvab035-B43","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/ccd.27461","article-title":"Application of the MADS classification system in a \u201cmega mammoth\u201d stent trial: feasibility and preliminary clinical implications","volume":"93","author":"Katsikis","year":"2019","journal-title":"Catheter Cardiovasc Interv"},{"key":"2021110402482602700_pvab035-B44","doi-asserted-by":"crossref","first-page":"e539","DOI":"10.4244\/EIJ-D-19-00184","article-title":"Validation of the updated logistic clinical SYNTAX score for all-cause mortality in the GLOBAL LEADERS trial","volume":"15","author":"Chichareon","year":"2019","journal-title":"EuroIntervention"},{"key":"2021110402482602700_pvab035-B45","article-title":"Usefulness of updated logistic clinical SYNTAX score based on MI-SYNTAX score in patients with ST-elevation myocardial infarction","author":"Kawashima","year":"2020","journal-title":"Catheter Cardiovasc Interv"},{"key":"2021110402482602700_pvab035-B46","doi-asserted-by":"crossref","first-page":"E516","DOI":"10.1002\/ccd.28898","article-title":"Usefulness of the updated logistic clinical SYNTAX score after percutaneous coronary intervention in patients with prior coronary artery bypass graft surgery: insights from the GLOBAL LEADERS trial","volume":"96","author":"Hara","year":"2020","journal-title":"Catheter Cardiovasc Interv"},{"key":"2021110402482602700_pvab035-B47","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ijcard.2019.02.043","article-title":"Predictive ability of ACEF and ACEF II score in patients undergoing percutaneous coronary intervention in the GLOBAL LEADERS study","volume":"286","author":"Chichareon","year":"2019","journal-title":"Int J Cardiol"},{"key":"2021110402482602700_pvab035-B48","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1055\/s-0040-1712449","article-title":"Comparative assessment of predictive performance of PRECISE-DAPT, CRUSADE, and ACUITY scores in risk stratifying 30-day bleeding events","volume":"120","author":"Kawashima","year":"2020","journal-title":"Thromb Haemost"},{"key":"2021110402482602700_pvab035-B49","doi-asserted-by":"crossref","DOI":"10.1093\/ehjcvp\/pvaa106","article-title":"PRECISE-DAPT score for bleeding risk prediction in patients on dual or single antiplatelet regimens: insights from the GLOBAL LEADERS and GLASSY","author":"Gragnano","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2021110402482602700_pvab035-B50","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1093\/eurheartj\/ehaa670","article-title":"Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS","volume":"41","author":"Baber","year":"2020","journal-title":"Eur Heart J"},{"key":"2021110402482602700_pvab035-B51","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1016\/j.jacc.2020.03.008","article-title":"Ticagrelor with or without aspirin in high-risk patients with diabetes mellitus undergoing percutaneous coronary intervention","volume":"75","author":"Angiolillo","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2021110402482602700_pvab035-B52","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1016\/j.jacc.2020.03.011","article-title":"Ticagrelor with or without aspirin after complex PCI","volume":"75","author":"Dangas","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2021110402482602700_pvab035-B53","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"key":"2021110402482602700_pvab035-B54","doi-asserted-by":"crossref","first-page":"e017109","DOI":"10.1161\/JAHA.120.017109","article-title":"Pooled analysis of bleeding, major adverse cardiovascular events, and all-cause mortality in clinical trials of time-constrained dual-antiplatelet therapy after percutaneous coronary intervention","volume":"9","author":"McClure","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2021110402482602700_pvab035-B55","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1161\/CIRCULATIONAHA.120.046251","article-title":"The safety and efficacy of aspirin discontinuation on a background of a P2Y(12) inhibitor in patients after percutaneous coronary intervention: a systematic review and meta-analysis","volume":"142","author":"O'Donoghue","year":"2020","journal-title":"Circulation"},{"key":"2021110402482602700_pvab035-B56","doi-asserted-by":"crossref","DOI":"10.1093\/ehjcvp\/pvaa119","article-title":"Effect of ticagrelor monotherapy on mortality after PCI: a systematic review and meta-analysis of randomized trials including 26143 patients","author":"Hong","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2021110402482602700_pvab035-B57","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/eurheartj\/ehaa739","article-title":"Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials","volume":"42","author":"Giacoppo","year":"2021","journal-title":"Eur Heart J"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvab035\/38526717\/pvab035.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ehjcvp\/article-pdf\/7\/6\/547\/41072925\/pvab035.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ehjcvp\/article-pdf\/7\/6\/547\/41072925\/pvab035.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T02:49:23Z","timestamp":1635994163000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/7\/6\/547\/6261071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,30]]},"references-count":57,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,4,30]]},"published-print":{"date-parts":[[2021,11,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvab035","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11]]},"published":{"date-parts":[[2021,4,30]]}}}